Inhibition of glioma progression by a newly discovered CD38 inhibitor
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Glioma, the most common cancer of the central nervous system, has very poor prognosis and no effective treatment. It has been shown that activated microglia/macrophages in the glioma tumor microenvironment support progression. Hence, inhibition of the supporting effect of these cells may constitute a useful therapeutic approach. Recently, using a syngeneic mouse glioma progression model, we showed that the ectoenzyme CD38 regulated microglia activation and, in addition, that the loss of CD38 from the tumor microenvironment attenuated glioma progression and prolonged the life span of the tumor‐bearing mice. These studies, which employed wild‐type (WT) and Cd38 −/− C57BL/6J mice, suggest that inhibition of CD38 in glioma microenvironment may be used as a new therapeutic approach to treat glioma. Our study tested this hypothesis. Initially, we found that the natural anthranoid, 4,5‐dihydroxyanthraquinone‐2‐carboxylic acid (rhein), and its highly water‐soluble tri‐potassium salt form (K‐rhein) are inhibitors of CD38 enzymatic (nicotinamide adenine dinucleotide glycohydrolase) activity (IC 50 = 1.24 and 0.84 μM, respectively, for recombinant mouse CD38). Treatment of WT, but not Cd38 −/− microglia with rhein and K‐rhein inhibited microglia activation features known to be regulated by CD38 (lipopolysaccharide/IFN‐γ‐induced activation, induced cell death and NO production). Furthermore, nasal administration of K‐rhein into WT, but not Cd38 −/− C57BL/6J, mice intracranially injected with GL261 cells substantially and significantly inhibited glioma progression. Hence, these results serve as a proof of concept, demonstrating that targeting CD38 at the tumor microenvironment by small‐molecule inhibitors of CD38, for example, K‐rhein, may serve as a useful therapeutic approach to treat glioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907
Regulation of innate immune responses in the brain
Rivest, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2565 · Cited by 843 · cited 1×
“” Activated microglia have been suggested to play both beneficial and harmful roles in various brain pathologies.(2,3) In pathological conditions, macrophages infiltrate the brain and act together with the resident microglia.”
BackgroundPartida-Sánchez, S., Cockayne, D. A., Monard, S., Jacobson, E. L., Oppenheimer, N., Garvy, B., Kusser, K., Goodrich, S., Howard, M., Harmsen, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1209 · Cited by 450
The role of microglia in central nervous system immunity and glioma immunology
Yang, I., Han, S. J., Kaur, G., Crane, C., & Parsa, A. T. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.05.006 · Cited by 410
Cited by
An Immune Atlas of Clear Cell Renal Cell Carcinoma
Chevrier, S., Levine, J. H., Zanotelli, V. R. T., Silina, K., Schulz, D., Bacac, M., Ries, C. H., Ailles, L., Jewett, M. A. S., Moch, H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.016 · Cited by 1,004
The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases
Hogan, K. A., Chini, C. C. S., & Chini, E. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01187 · Cited by 337
The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging
Chini, E. N., Chini, C. C. S., Espindola Netto, J. M., de Oliveira, G. C., & van Schooten, W. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.02.001 · Cited by 227
“The beneficial effects of flavonoid CD38 inhibitors were reported in animal models of obesity, heart ischemia, kidney injury, viral infection, and cancer [71-77].”
InfluentialChallenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy
Upton, D. H., Ung, C., George, S. M., Tsoli, M., Kavallaris, M., & Ziegler, D. S. (2022) · Theranostics · doi:10.7150/thno.69682 · Cited by 182
Luteolinidin Protects the Postischemic Heart through CD38 Inhibition with Preservation of NAD(P)(H)
Boslett, J., Hemann, C., Zhao, Y. J., Lee, H.-C., & Zweier, J. L. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239459 · Cited by 69
Boslett, J., Reddy, N., Alzarie, Y. A., & Zweier, J. L. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254557 · Cited by 43
“Thus, there is a great need for the development of CD38 inhibitors (Choe et al., 2011; Kellenberger et al., 2011; Moreau et al., 2013; Wang et al., 2014; Becherer et al., 2015; Blacher et al., 2015; Haffner et al., 2015).”
Background
Metadata
- Authors
- Blacher, E., Ben Baruch, B., Levy, A., Geva, N., Green, K. D., Garneau‐Tsodikova, S., Fridman, M., & Stein, R.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2014-08-07
- Volume
- 136
- Issue
- 6
- Pages
- 1422-1433
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1850228883
- Cited by
- 69
- References
- 4
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.